がん支持療法薬の市場規模、シェア、成長分析：治療クラス別、用途別、流通チャネル別、地域別 - 産業予測 2025～2032年

がん支持療法薬の市場規模は2023年に217億5,000万米ドルとなり、予測期間（2025-2032年）のCAGRは3.0%で、2024年の224億米ドルから2032年には283億8,000万米ドルに成長する見通しです。

がん支持療法薬の世界市場は、がん治療の副作用を緩和し、患者のQOLを高める上で極めて重要です。がん罹患率の上昇、人口の高齢化、がん治療における画期的な進歩により、この分野は大きな成長を遂げています。制吐剤、鎮痛剤、造血剤などの支持療法薬は、吐き気、疼痛、血球数低下などの副作用の管理に不可欠です。現在進行中の研究開発では、より的を絞った治療法の開発に焦点が当てられており、製薬会社間の協力により、支持療法をがん治療と統合する治療の選択肢が広がっています。患者中心の治療が強化され、治療中のQOL維持の重要性が認識されるにつれ、これらの薬剤の需要は引き続き拡大し、技術革新が促進され、患者の快適性が高まると予想されます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 規制情勢
• 特許分析

がん支持療法薬市場規模：治療クラス別& CAGR（2025-2032）

• 市場概要
• 顆粒球コロニー刺激因子（G-CSF）
• 赤血球造血刺激因子（ESA）
• 制吐剤
• ビスフォスフォネート
• オピオイド
• 非ステロイド性抗炎症薬（NSAID）

がん支持療法薬市場規模：用途別& CAGR（2025-2032）

• 市場概要
• 化学療法誘発性悪心・嘔吐（CINV）
• 化学療法誘発性貧血
• 化学療法誘発性好中球減少症
• 骨転移
• がんの痛み
• その他

がん支持療法薬市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

がん支持療法薬市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Amgen Inc.（USA）
• Merck & Co., Inc.（USA）
• Johnson & Johnson Services, Inc.（USA）
• Novartis AG（Switzerland）
• F. Hoffmann-La Roche AG（Switzerland）
• Sanofi（France）
• Pfizer Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Helsinn Healthcare（Switzerland）
• Heron Therapeutics, Inc.（USA）
• Acacia Pharma Group Plc（UK）
• Sun Pharmaceutical Industries Ltd.（India）
• Celldex Therapeutics（USA）
• Ipsen Pharma（France）
• GlaxoSmithKline plc（UK）
• Bayer AG（Germany）
• Takeda Pharmaceutical Company Limited（Japan）
• Mylan N.V.（USA）
• Dr. Reddy's Laboratories Ltd.（India）
• Eli Lilly and Company（USA）

結論と提言

Cancer Supportive Care Drugs Market size was valued at USD 21.75 billion in 2023 and is poised to grow from USD 22.4 billion in 2024 to USD 28.38 billion by 2032, growing at a CAGR of 3.0% during the forecast period (2025-2032).

The global market for cancer supportive care drugs is pivotal in alleviating the adverse effects of cancer treatments and enhancing patients' quality of life. With rising cancer incidence, an aging population, and breakthroughs in cancer therapies, this sector has experienced significant growth. Supportive care drugs, including antiemetics, analgesics, and hematopoietic agents, are essential in managing side effects such as nausea, pain, and low blood cell counts. Ongoing research and development efforts are focused on creating more targeted therapies, and collaborations among pharmaceutical companies are expanding treatment options to integrate supportive care with cancer treatments. As the focus on patient-centered care intensifies and the importance of maintaining quality of life during treatment gains recognition, demand for these drugs is expected to continue to grow, driving innovation and enhancing patient comfort.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cancer Supportive Care Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cancer Supportive Care Drugs Market Segments Analysis

Global Cancer Supportive Care Drugs Market is segmented by Therapeutic Class, Application, Distribution Channel and region. Based on Therapeutic Class, the market is segmented into Granulocyte Colony-Stimulating Factors (G-CSFs), Erythropoiesis-Stimulating Agents (ESAs), Antiemetics, Bisphosphonates, Opioids and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). Based on Application, the market is segmented into Chemotherapy-Induced Nausea and Vomiting (CINV), Chemotherapy-Induced Anemia, Chemotherapy-Induced Neutropenia, Bone Metastasis, Cancer Pain and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Cancer Supportive Care Drugs Market

The escalating incidence of cancer worldwide significantly drives the demand for cancer supportive care drugs. As more patients receive treatments such as chemotherapy, radiation therapy, and targeted therapies, the necessity to manage the adverse effects associated with these procedures becomes increasingly critical. Supportive care drugs play a vital role in enhancing patients' quality of life by alleviating symptoms such as nausea, pain, anemia, and fatigue, which often accompany cancer treatments. Consequently, the growing population of cancer patients seeking effective relief options underscores the importance of these drugs in the therapeutic landscape, further propelling market growth in the cancer supportive care segment.

Restraints in the Cancer Supportive Care Drugs Market

The high cost of cancer supportive care drugs presents a significant challenge in the market, potentially limiting their accessibility and usage. For many cancer patients, especially those in regions with limited healthcare insurance or inadequate government-funded healthcare programs, the financial burden can be overwhelming. This steep pricing may deter patients from utilizing these essential medications, which are crucial for managing treatment side effects. Consequently, this economic restraint can hinder effective cancer care, ultimately impacting patients' quality of life and their ability to cope with the rigorous demands of their treatment regimen.

Market Trends of the Cancer Supportive Care Drugs Market

The Cancer Supportive Care Drugs market is experiencing a significant trend towards personalized supportive care, driven by advancements in individualized cancer treatments. As therapies become more tailored to specific cancer types and patient characteristics, there is a growing demand for supportive care medications designed to alleviate unique side effects such as chemotherapy-induced nausea, vomiting, pain, fatigue, and anemia. This targeted approach enhances patient quality of life and fosters better treatment adherence, ultimately improving overall outcomes. With the increasing recognition of the importance of supportive care in holistic cancer management, the market is poised for robust growth, reflecting the evolving needs of patients and healthcare providers.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Cancer Supportive Care Drugs Market Size by Therapeutic Class & CAGR (2025-2032)

• Market Overview
• Granulocyte Colony-Stimulating Factors (G-CSFs)
• Erythropoiesis-Stimulating Agents (ESAs)
• Antiemetics
• Bisphosphonates
• Opioids
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Global Cancer Supportive Care Drugs Market Size by Application & CAGR (2025-2032)

• Market Overview
• Chemotherapy-Induced Nausea and Vomiting (CINV)
• Chemotherapy-Induced Anemia
• Chemotherapy-Induced Neutropenia
• Bone Metastasis
• Cancer Pain
• Others

Global Cancer Supportive Care Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Cancer Supportive Care Drugs Market Size & CAGR (2025-2032)

• North America (Therapeutic Class, Application, Distribution Channel)
  • US
  • Canada
• Europe (Therapeutic Class, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapeutic Class, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapeutic Class, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapeutic Class, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Helsinn Healthcare (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Heron Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acacia Pharma Group Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celldex Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations